Anne Pariser

1.9k citations

35 papers · 782 indexed · 1 hit paper · h-index 17

Impact in

Health Informatics top 10%
Genetics top 10%
- Genomics and Rare Diseases
- Neurogenetic and Muscular Disorders Research

Papers in ⓘ

Genetics 17
- Genomics and Rare Diseases 16
Molecular Biology 15
- CRISPR and Genetic Engineering 8
- Biochemical and Molecular Research 4
- Biomedical Text Mining and Ontologies 4

Co-authors: Petra Kaufmann (1 shared paper)Christopher P. Austin (1 shared paper)Amy S. Rosenberg (2 shared papers)Annie Kennedy (1 shared paper)Elizabeth W. Shores (1 shared paper)Jay N. Lozier (1 shared paper)Daniela Verthelyi (1 shared paper)Jinhai Wang (1 shared paper)
Journals: Orphanet Journal of Rare Diseases (6 papers)Molecular Genetics and Metabolism (2 papers)Nature Reviews Drug Discovery (2 papers)Therapeutic Innovation & Regulatory Science (2 papers)Journal of Biopharmaceutical Statistics (2 papers)
Partner nations: United States Canada Australia

In The Last Decade

Anne Pariser

33 papers receiving 754 citations

Hit Papers

align trajectories log scale

The national economic burden of rare disease in the United States in 2019 2022 · 98 citations

Peers

Countries citing papers authored by Anne Pariser

Since Specialization

Citations

This map shows the geographic impact of Anne Pariser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Pariser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Pariser more than expected).

Fields of papers citing papers by Anne Pariser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Pariser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Pariser. The network helps show where Anne Pariser may publish in the future.

Co-authors

The 25 scholars most cited alongside Anne Pariser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anne Pariser Line = papers co-authored together Anne Pariser links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment Nature Biotechnology ·Jinhai Wang, Jay N. Lozier, Gibbes R. Johnson, Susan Kirshner, Daniela Verthelyi, Anne Pariser, Elizabeth W. Shores, Amy S. Rosenberg	2008	130
2	The national economic burden of rare disease in the United States in 2019 Orphanet Journal of Rare Diseases ·Grace Yang, Inna Cintina, Anne Pariser, Elisabeth Oehrlein, Jamie Sullivan, Annie Kennedy Hit paper breakdown →	2022	98
3	From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research Orphanet Journal of Rare Diseases ·Petra Kaufmann, Anne Pariser, Christopher P. Austin	2018	91
4	The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems Orphanet Journal of Rare Diseases ·Ainslie Tisdale, Christine M. Cutillo, Ramaa Nathan, Pierantonio Russo, Bryan Laraway, Melissa Haendel, Douglas Nowak, Cindy Hasche, Chun‐Hung Chan, Emily R. Griese, Hugh Dawkins, Oodaye Shukla, David A. Pearce, Joni L. Rutter, Anne Pariser	2021	53
5	Rare Cancer Trial Design: Lessons from FDA Approvals Clinical Cancer Research ·Himabindu Gaddipati, Ke Liu, Anne Pariser, Richard Pazdur	2012	49
6	Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities PET Clinics ·Navid Hasani, Faraz Farhadi, Michael Morris, Moozhan Nikpanah, Arman Rahmim, Yanji Xu, Anne Pariser, Michael T. Collins, Ronald M. Summers, Elizabeth C. Jones, Eliot L. Siegel, Babak Saboury	2021	32
7	Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015 Journal of Women s Health ·Alice Chen, Hilary Wright, Hawi Itana, Merina Elahi, Ayomide Igun, Guoxing Soon, Anne Pariser, Emmanuel O. Fadiran	2017	30
8	Important Role of Translational Science in Rare Disease Innovation, Discovery, and Drug Development Journal of General Internal Medicine ·Anne Pariser, William A. Gahl	2014	29
9	An integrative knowledge graph for rare diseases, derived from the Genetic and Rare Diseases Information Center (GARD) Journal of Biomedical Semantics ·Qian Zhu, Ðắc-Trung Nguyễn, Ivan Grishagin, Noel Southall, Eric Sid, Anne Pariser	2020	26
10	Cross-sector sponsorship of research in eosinophilic esophagitis: A collaborative model for rational drug development in rare diseases Journal of Allergy and Clinical Immunology ·Robert P. Fiorentino, Gumei Liu, Anne Pariser, Andrew E. Mulberg	2012	25
11	Accelerating orphan drug development Nature Reviews Drug Discovery ·Timothy R. Coté, Kui Xu, Anne Pariser	2010	22
12	Clinical pharmacology as a cornerstone of orphan drug development Nature Reviews Drug Discovery ·Edward D. Bashaw, Shiew‐Mei Huang, Timothy R. Coté, Anne Pariser, Christine Garnett, Gilbert J. Burckart, Lei Zhang, Angela Men, Christine D. Le, Rosane Charlab, Jogaro V. Gobburu, Lawrence J. Lesko	2011	19
13	The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease American Journal of Medical Genetics Part C Seminars in Medical Genetics ·Emanuela Lacaná, Lynne Yao, Anne Pariser, Amy S. Rosenberg	2012	18
14	Research challenges in central nervous system manifestations of inborn errors of metabolism Molecular Genetics and Metabolism ·Patricia Dickson, Anne Pariser, Stephen C. Groft, Rieko Ishihara, D. Elizabeth McNeil, Danilo A. Tagle, Donna Griebel, Stephen G. Kaler, Jonathan W. Mink, Elsa Shapiro	2010	18
15	Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases Therapeutic Innovation & Regulatory Science ·Carla Epps, Ralph Bax, Alysha Croker, Dionna Green, Andrea Gropman, Ágnes Klein, Hannah Landry, Anne Pariser, Marc B. Rosenman, Michiyo Sakiyama, Junko Sato, Kuntal Sen, Monique Stone, Fumi Takeuchi, Jonathan M. Davis	2022	16
16	Therapies for Inborn Errors of Metabolism: What Has the Orphan Drug Act Delivered? PEDIATRICS ·Sonali S. Talele, Kui Xu, Anne Pariser, M. Miles Braun, Sheiren Farag-El-Massah, M. Ian Phillips, Barry H. Thompson, Timothy R. Coté	2010	16
17	Training the Translational Scientist Science Translational Medicine ·Rebecca D. Jackson, Sherine E. Gabriel, Anne Pariser, Peter U. Feig	2010	16
18	A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins Clinical Immunology ·Aaron S. Rosenberg, Anne Pariser, Betty Diamond, Lynne Yao, Laurence A. Turka, Emanuela Lacaná, Priya S. Kishnani	2016	14
19	Characteristics of rare disease marketing applications associated with FDA product approvals 2006–2010 Drug Discovery Today ·Anne Pariser, Daniel J. Slack, Larry Bauer, Catherine A. Warner, LaRee Tracy	2012	13
20	Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials. PubMed ·Anne Pariser, Kui Xu, John Milto, Timothy R. Coté	2011	12

About Anne Pariser

Anne Pariser is a scholar working on Genetics, Molecular Biology, Economics and Econometrics, Public Health, Environmental and Occupational Health and Pediatrics, Perinatology and Child Health, having authored 35 papers that have together received 782 indexed citations. Recurring topics across this work include Genomics and Rare Diseases (16 papers), CRISPR and Genetic Engineering (8 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers), Pharmaceutical Economics and Policy (6 papers), Pharmaceutical studies and practices (5 papers), Biochemical and Molecular Research (4 papers), Biomedical Text Mining and Ontologies (4 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Health Informatics (16 citations), Genetics (229 citations), Physiology (154 citations), Genetics (60 citations) and Economics and Econometrics (137 citations). Anne Pariser has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Petra Kaufmann, Christopher P. Austin, Amy S. Rosenberg, Annie Kennedy, Elizabeth W. Shores, Jay N. Lozier, Daniela Verthelyi, Jinhai Wang, Elisabeth Oehrlein and Inna Cintina. Their work appears in journals such as Orphanet Journal of Rare Diseases, Molecular Genetics and Metabolism, Nature Reviews Drug Discovery, Therapeutic Innovation & Regulatory Science and Journal of Biopharmaceutical Statistics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact